As the hyperphagia and obesity of TRPC5 deficiency are mediated by impaired activation of Pomc neurons, this disorder may be treatable with an MC4R agonist licensed for the treatment of genetic obesity syndromes.58–60 OXT receptor agonists or gene therapy to restore TRPC5 expression in specific areas of the hypothalamus are other potential therapeutic strategies. Here, MC4R is linked to hyperinsulinemic hypoglycemia, familial, 4.